Paper575122
Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II).
Douple EB and 1 other. Int J Radiat Oncol Biol Phys, 1979. Cited by 117 papers, by iCite.
Cite this record
ConductScience Library. Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Papers, record 575122. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/575122
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II).
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Cisplatin | Major topic |
| Mammary Neoplasms, Experimental | Major topic |
| Oxygen | Major topic |
| Radiation-Sensitizing Agents | Major topic |
| Animals | |
| Dose-Response Relationship, Radiation | |
| Female | |
| Hypoxia | |
| Mice | |
| Mice, Inbred C3H | |
| Time Factors |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 26495872 | Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine. | Br J Radiol | 2016 | https://conductscience.org/library/papers/26495872 | PubMed |
| 19860913 | Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. | Radiat Oncol | 2009 | https://conductscience.org/library/papers/19860913 | PubMed |
| 19461907 | Chemoradiotherapy for esophageal cancer. | Gastrointest Cancer Res | 2009 | https://conductscience.org/library/papers/19461907 | PubMed |
| 8519652 | Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. | Br J Cancer | 1995 | https://conductscience.org/library/papers/8519652 | PubMed |
| 7547255 | Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7547255 | PubMed |
| 6932930 | An appraisal of in vivo assays of excised tumours. | Br J Cancer Suppl | 1980 | https://conductscience.org/library/papers/6932930 | PubMed |
| 6682105 | Daily cis-dichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. | J Cancer Res Clin Oncol | 1983 | https://conductscience.org/library/papers/6682105 | PubMed |
| 6203548 | Interactions of radiation and adriamycin, bleomycin, mitomycin C or cis-diamminedichloroplatinum II in intestinal crypt cells. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6203548 | PubMed |
| 3606943 | Response of an ocular melanoma to subconjunctival injection of 5-thio-D-glucose or cis-platin. | Br J Cancer | 1987 | https://conductscience.org/library/papers/3606943 | PubMed |
| 1503898 | The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1503898 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/575122
GET https://conductscience.org/api/papers/v1/575122/authors